Harlequins: Is owner joining board a cause for concern for Prem Rugby club? March 27, 2026 It is not uncommon for rugby clubs and their associated companies to appoint directors to their boards; it happens quite often and the more eye-catching news tends to relate to individuals who are removed from their posts. Take the departure of Lloyd’s of London’s chief financial officer Alexandra Cliff from the Saracens board after less [...]
NS&I set to fork out millions over huge missing savings scandal March 26, 2026 National Savings and Investments (NS&I) is set to fork out millions of pounds to customers following a missing savings scandal. The government-backed bank is expected to pay out to customers who claim there have been failures in managing their money, with failings dating back years, according to reports in The Telegraph. The bank has been [...]
How Bishopsgate became London’s Midtown Manhattan for law firms March 26, 2026 If you’ve had the pleasure of visiting a top law firm in London, you might mistake yourself for being in an episode of smash US legal drama (and Duchess of Sussex starring) Suits. Increasingly City firms’ offices have a more American feel to them. In the City of London, it is not just a race [...]
Vodafone set for £85m court showdown with ex-franchisees March 26, 2026 An £85m court battle between Vodafone and its former franchisees will kick off on Thursday over claims the telecoms giant imposed cuts on franchises which left managers facing closures and bankruptcy. The 62 ex-franchisees pursuing a civil action against Vodafone – recently renamed VodafoneThree – will launch their case at the High Court for the [...]
Iran war throws gold’s shine under the spotlight March 25, 2026 The ongoing conflict in the Middle East has thrown gold’s safe haven status into question after the asset suffered a sharp selloff. The price of gold has tumbled by more than 15 per cent since the start of the Iran war, despite holding pre-war levels for the first initial 10 days of the conflict as [...]
Blackrock boss Larry Fink says AI will boost trade jobs March 25, 2026 Society needs to rethink its view of careers as AI reshapes the job market, Blackrock chief Larry Fink has said, warning that skilled trades like plumbing and electrical work will become more valuable while some office roles decline. In an interview with the BBC, the asset manager boss claimed the US had “overdid” its push [...]
NS&I under fire for ‘short-changing’ bereavers March 25, 2026 The UK’s state-owned savings giant is facing mounting backlash over its handling bereaved families’ savings. National Savings and Investments (NS&I) – formerly called the Post Office Savings Bank – has faced criticism for leaving families of deceased savers forced to call in lawyers to claw back their rightful cash. The Treasury-backed vehicle, which holds around £250bn [...]
Trian and General Catalyst Agree to Increase Merger Consideration to $52.00 Per Share in Cash for Janus Henderson Group plc and Have Made the Only Actionable Proposal March 24, 2026 Amended Merger Agreement Represents a $3.00 All-Cash Price Increase; 25% Premium to Unaffected Share Price; Parties Committed to Closing by Mid-2026 Special Committee Determines that Victory Capital’s Revised Unsolicited March 17, 2026 Proposal Is Not Actionable and Is Not in Best Interests of Janus Henderson and Its Shareholders Amended Merger Agreement’s All-Cash Transaction With Trian and General Catalyst Is Superior From an Expected Value and Certainty Perspective and Is the Only Actionable Proposal
ICON and Advarra Introduce New ‘Research-Ready,’ Connected Site Network Model March 24, 2026 Partnership will integrate ICON’s clinical trial technology with Advarra’s purpose-built system for research sites, embedded across a broad, deeply established global network. Partnership will reduce administrative friction, accelerate study startup, and increase clinical trial participation.
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights March 24, 2026 COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect in treatment resistant depression (TRD), with a generally well-tolerated and safe profile Across three large trials in TRD, including two positive Phase 3 studies, COMP360’s differentiated profile is redefining rapidity and durability for TRD patients and demonstrating a consistent level of clinical effect that has never been achieved before Compass will meet with the FDA to confirm alignment on a rolling submission and review, and expects to complete the NDA submission in Q4 Compass is rapidly advancing commercial readiness plans and expects COMP360 will fit seamlessly across diverse healthcare settings at launch Phase 2b/3 trial in PTSD initiating, following FDA acceptance of IND application Successful $150 million financing in February and exercise of $200 million in warrants extends cash runway into 2028